title: Combined reserpine and pituitary irradiation therapy for Cushing's disease patients following unsuccessful transsphenoidal microsurgery.
abstract: The effectiveness of treatment with reserpine and pituitary irradiation, and with reserpine alone was evaluated in three female patients with Cushing's disease whose transsphenoidal pituitary microsurgery (TPM) had been unsuccessful. In these patients, endocrinological examination after the surgery demonstrated a recurrence of the disease although the microadenomas had apparently been curetted out from the pituitary in all patients. The first patient therefore received 1.0-2.0 mg/day of reserpine with 60 Gy x-ray irradiation, and there was complete remission within 3 months and the patient remained asymptomatic even when reserpine was reduced to 0.1 mg/day 10 years later. The second case was treated with low dose x-ray (20 Gy) and reserpine (0.5-2.0 mg/day), which were also effective. However, 2 weeks discontinuation of the drug caused urinary 17-hydroxycorticosteroids (17-OHCS) and serum cortisol to increase abnormally again, but these were finally re-normalized by an additional administration of reserpine. The third case was given reserpine alone (1.0-2.0 mg/day). She also had a remission in 3 months and the treatment was continued for one year, requiring no further treatment. These results suggest that additional treatment with reserpine and pituitary irradiation or with reserpine alone after unsuccessful TPM may be an effective alternative for patients with Cushing's disease.
authors.affiliation: Third Department of Internal Medicine, Kumamoto University Medical School, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Sasaki
authors.forename: T
authors.initials: T
authors.lastname: Umeda
authors.forename: T
authors.initials: T
authors.lastname: Iwaoka
authors.forename: J
authors.initials: J
authors.lastname: Inoue
authors.forename: T
authors.initials: T
authors.lastname: Sato
mesh_terms: D015065:17-Hydroxycorticosteroids / Q000652:urine; D000236:Adenoma / Q000150:complications / Q000628:therapy*; D000324:Adrenocorticotropic Hormone / Q000097:blood; D000328:Adult; D003131:Combined Modality Therapy; D003480:Cushing Syndrome / Q000209:etiology / Q000628:therapy*; D003907:Dexamethasone / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008866:Microsurgery / Q000379:methods*; D008875:Middle Aged; D010910:Pituitary Irradiation; D010911:Pituitary Neoplasms / Q000150:complications / Q000628:therapy*; D012110:Reserpine / Q000627:therapeutic use*; D013101:Sphenoid Sinus
chemical_list: D015065:17-Hydroxycorticosteroids; D003907:Dexamethasone; D012110:Reserpine; D000324:Adrenocorticotropic Hormone; D006854:Hydrocortisone